BACKGROUND. To determine the effects of etidronate (a bisphosphonate that inhibits osteoclast-mediated bone resorption) in the treatment of postmenopausal osteoporosis, we conducted a prospective, two-year, double-blind, placebo-controlled, multicenter study in 429 women who had one to four vertebral compression fractures plus radiographic evidence of osteopenia. METHODS. The patients were randomly assigned to treatment with phosphate (1.0 g) or placebo twice daily on days 1 through 3, etidronate (400 mg) or placebo daily on days 4 through 17, and supplemental calcium (500 mg) daily on days 18 through 91 (group 1, placebo and placebo; group 2, phosphate and placebo; group 3, placebo and etidronate; and group 4, phosphate and etidronate). The treatment cycles were repeated eight times. The bone density of the spine was measured by dual-photon absorptiometry, and the rates of new vertebral fractures were determined from sequential radiographs. RESULTS. After two years, the patients receiving etidronate (groups 3 and 4) had significant increases in their mean (+/- SE) spinal bone density (4.2 +/- 0.8 percent and 5.2 +/- 0.7 percent, respectively; P less than 0.017). The rate of new vertebral fractures was reduced by half in the etidronate-treated patients (groups 3 and 4 combined) as compared with the patients who did not receive etidronate (groups 1 and 2 combined) (29.5 vs. 62.9 fractures per 1000 patient-years; P = 0.043); the effect of treatment was most striking in the subgroup of patients with the lowest spinal bone mineral density at base line, in whom fracture rates were reduced by two thirds (42.3 vs. 132.7 fractures per 1000 patient-years; P = 0.004). The addition of phosphate provided no apparent benefit. There were no significant adverse effects of treatment. CONCLUSIONS. Intermittent cyclical therapy with etidronate for two years significantly increases spinal bone mass and reduces the incidence of new vertebral fractures in women with postmenopausal osteoporosis.
Source Information
Emory University School of Medicine, Atlanta, GA.
This article has been cited by other articles:
Papapoulos, S E, Schimmer, R C
(2008). Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate. Postgrad. Med. J.
84: 307-312
[Abstract][Full Text]
Papapoulos, S E, Schimmer, R C
(2007). Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate. Ann Rheum Dis
66: 853-858
[Abstract][Full Text]
Russell, R. G. G.
(2007). Bisphosphonates: Mode of Action and Pharmacology. Pediatrics
119: S150-S162
[Abstract][Full Text]
Karlsson, M. K., Gerdhem, P., Ahlborg, H. G.
(2005). The prevention of osteoporotic fractures. J Bone Joint Surg Br
87-B: 1320-1327
[Full Text]
Hodsman, A. B., Bauer, D. C., Dempster, D. W., Dian, L., Hanley, D. A., Harris, S. T., Kendler, D. L., McClung, M. R., Miller, P. D., Olszynski, W. P., Orwoll, E., Yuen, C. K.
(2005). Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis: A Review of the Evidence and Suggested Guidelines for Its Use. Endocr. Rev.
26: 688-703
[Abstract][Full Text]
Ioannidis, J. P. A.
(2005). Contradicted and Initially Stronger Effects in Highly Cited Clinical Research. JAMA
294: 218-228
[Abstract][Full Text]
Morris, C. D., Einhorn, T. A.
(2005). Bisphosphonates in Orthopaedic Surgery. JBJS
87: 1609-1618
[Abstract][Full Text]
Campbell, I A, Douglas, J G, Francis, R M, Prescott, R J, Reid, D M
(2004). Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids. Thorax
59: 761-768
[Abstract][Full Text]
Francis, R.M., Baillie, S.P., Chuck, A.J., Crook, P.R., Dunn, N., Fordham, J.N., Kelly, C., Rodgers, A.
(2004). Acute and long-term management of patients with vertebral fractures. QJM
97: 63-74
[Abstract][Full Text]
Santini, D., Vespasiani Gentilucci, U., Vincenzi, B., Picardi, A., Vasaturo, F., La Cesa, A., Onori, N., Scarpa, S., Tonini, G.
(2003). The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol
14: 1468-1476
[Abstract][Full Text]
Santini, D., Vincenzi, B., Dicuonzo, G., Avvisati, G., Massacesi, C., Battistoni, F., Gavasci, M., Rocci, L., Tirindelli, M. C., Altomare, V., Tocchini, M., Bonsignori, M., Tonini, G.
(2003). Zoledronic Acid Induces Significant and Long-Lasting Modifications of Circulating Angiogenic Factors in Cancer Patients. Clin. Cancer Res.
9: 2893-2897
[Abstract][Full Text]
Woolf, A. D, Akesson, K.
(2003). Preventing fractures in elderly people. BMJ
327: 89-95
[Full Text]
Brown, T. E. R.
(2003). Osteoporosis: A Pharmacotherapy Update. Journal of Pharmacy Practice
16: 164-169
[Abstract]
Brown, J. P., Josse, R. G.
(2003). Lignes directrices de pratique clinique 2002 pour le diagnostic et le traitement de l'osteoporose au Canada. CMAJ
168: SF1-38
[Abstract][Full Text]
Brown, J. P., Josse, R. G.
(2002). 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ
167: s1-34
[Abstract][Full Text]
Tuck, S P, Francis, R M
(2002). Osteoporosis. Postgrad. Med. J.
78: 526-532
[Abstract][Full Text]
Lehmann, H J, Mouritzen, U, Christgau, S, Cloos, P A C, Christiansen, C
(2002). Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products. Ann Rheum Dis
61: 530-533
[Abstract][Full Text]
Hodsman, A. B., Hanley, D. A., Josse, R.
(2002). Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date. CMAJ
166: 1426-1430
[Full Text]
Reid, I. R., Brown, J. P., Burckhardt, P., Horowitz, Z., Richardson, P., Trechsel, U., Widmer, A., Devogelaer, J.-P., Kaufman, J.-M., Jaeger, P., Body, J.-J., Brandi, M. L., Broell, J., Di Micco, R., Genazzani, A. R., Felsenberg, D., Happ, J., Hooper, M. J., Ittner, J., Leb, G., Mallmin, H., Murray, T., Ortolani, S., Rubinacci, A., Saaf, M., Samsioe, G., Verbruggen, L., Meunier, P. J.
(2002). Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral Density. NEJM
346: 653-661
[Abstract][Full Text]
Marcus, R., Wong, M., Heath, H. III, Stock, J. L.
(2002). Antiresorptive Treatment of Postmenopausal Osteoporosis: Comparison of Study Designs and Outcomes in Large Clinical Trials with Fracture as an Endpoint. Endocr. Rev.
23: 16-37
[Abstract][Full Text]
Gehlbach, S. H., Fournier, M., Bigelow, C.
(2002). Recognition of Osteoporosis by Primary Care Physicians. Am. J. Public Health
92: 271-273
[Abstract][Full Text]
Rubin, C. D., Pak, C. Y. C., Adams-Huet, B., Genant, H. K., Li, J., Rao, D. S.
(2001). Sustained-Release Sodium Fluoride in the Treatment of the Elderly With Established Osteoporosis. Arch Intern Med
161: 2325-2333
[Abstract][Full Text]
GROTZ, W., NAGEL, C., POESCHEL, D., CYBULLA, M., PETERSEN, K.-G., UHL, M., STREY, C., KIRSTE, G., OLSCHEWSKI, M., REICHELT, A., RUMP, L. C.
(2001). Effect of Ibandronate on Bone Loss and Renal Function after Kidney Transplantation. J. Am. Soc. Nephrol.
12: 1530-1537
[Abstract][Full Text]
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., Wang, O., Mitlak, B. H., Mellstrom, D., Oefjord, E. S., Marcinowska-Suchowierska, E., Salmi, J., Mulder, H., Halse, J., Sawicki, A. Z.
(2001). Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis. NEJM
344: 1434-1441
[Abstract][Full Text]
Harris, S. T., Eriksen, E. F., Davidson, M., Ettinger, M. P., Moffett, A. H. Jr., Baylink, D. J., Crusan, C. E., Chines, A. A.
(2001). Effect of Combined Risedronate and Hormone Replacement Therapies on Bone Mineral Density in Postmenopausal Women. J. Clin. Endocrinol. Metab.
86: 1890-1897
[Abstract][Full Text]
Kurland, E. S., Cosman, F., McMahon, D. J., Rosen, C. J., Lindsay, R., Bilezikian, J. P.
(2000). Parathyroid Hormone as a Therapy for Idiopathic Osteoporosis in Men: Effects on Bone Mineral Density and Bone Markers. J. Clin. Endocrinol. Metab.
85: 3069-3076
[Abstract][Full Text]
Francis, R.M., Baillie, S.P., Chuck, A.J., Crook, P.R., Daymond, T., Dunn, N., Fordham, J.N., Kelly, C., Rodgers, A.
(2000). Management of osteoporosis in patients with hip fractures. QJM
93: 501-506
[Full Text]
Freedman, K. B., Kaplan, F. S., Bilker, W. B., Strom, B. L., Lowe, R. A.
(2000). Treatment of Osteoporosis: Are Physicians Missing an Opportunity?*{{dagger}}. JBJS
82: 1063-1063
[Abstract][Full Text]
Fogelman, I., Ribot, C., Smith, R., Ethgen, D., Sod, E., Reginster, J.-Y.
(2000). Risedronate Reverses Bone Loss in Postmenopausal Women with Low Bone Mass: Results From a Multinational, Double-Blind, Placebo-Controlled Trial. J. Clin. Endocrinol. Metab.
85: 1895-1900
[Abstract][Full Text]
Pfeilschifter, J., Diel, I. J.
(2000). Osteoporosis Due to Cancer Treatment: Pathogenesis and Management. JCO
18: 1570-1593
[Abstract][Full Text]
Scott, E M, Gaywood, I, Scott, B B
(2000). Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. Gut
46: I1-8
[Full Text]
Srivastava, T., Alon, U. S.
(1999). Bisphosphonates: From Grandparents to Grandchildren. CLIN PEDIATR
38: 687-702
[Abstract]
Bucher, H. C., Guyatt, G. H., Cook, D. J., Holbrook, A., McAlister, F. A., for the Evidence-Based Medicine Working Group,
(1999). Users' Guides to the Medical Literature: XIX. Applying Clinical Trial Results; A. How to Use an Article Measuring the Effect of an Intervention on Surrogate End Points. JAMA
282: 771-778
[Full Text]
Miller, P. D., Zapalowski, C., Kulak, C. A. M., Bilezikian, J. P.
(1999). Bone Densitometry: The Best Way to Detect Osteoporosis and to Monitor Therapy. J. Clin. Endocrinol. Metab.
84: 1867-1871
[Full Text]
Greenspan, S. L.
(1999). A 73-Year-Old Woman With Osteoporosis. JAMA
281: 1531-1540
[Full Text]
Masud, T, Mulcahy, B, Thompson, A V, Donnelly, S, Keen, R W, Doyle, D V, Spector, T D
(1998). Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women. Ann Rheum Dis
57: 346-349
[Abstract][Full Text]
Roux, C., Oriente, P., Laan, R., Hughes, R. A., Ittner, J., Goemaere, S., Di Munno, O., Pouillès, J. M., Horlait, S., Cortet, B.
(1998). Randomized Trial of Effect of Cyclical Etidronate in the Prevention of Corticosteroid-Induced Bone Loss. J. Clin. Endocrinol. Metab.
83: 1128-1133
[Abstract][Full Text]
Eastell, R.
(1998). Treatment of Postmenopausal Osteoporosis. NEJM
338: 736-746
[Full Text]
Hosking, D., Chilvers, C. E.D., Christiansen, C., Ravn, P., Wasnich, R., Ross, P., McClung, M., Balske, A., Thompson, D., Daley, M., Yates, A. J., The Early Postmenopausal Intervention Cohort Study,
(1998). Prevention of Bone Loss with Alendronate in Postmenopausal Women under 60 Years of Age. NEJM
338: 485-492
[Abstract][Full Text]
Fleisch, H.
(1998). Bisphosphonates: Mechanisms of Action. Endocr. Rev.
19: 80-100
[Abstract][Full Text]
Meunier, P. J., Confavreux, E., Tupinon, I., Hardouin, C., Delmas, P. D., Balena, R.
(1997). Prevention of Early Postmenopausal Bone Loss with Cyclical Etidronate Therapy (A Double-Blind, Placebo-Controlled Study and 1-Year Follow-Up). J. Clin. Endocrinol. Metab.
82: 2784-2791
[Abstract][Full Text]
TOBIAS, J. H
(1997). How do bisphosphonates prevent fractures?. Ann Rheum Dis
56: 510-511
[Full Text]
Holloway, L., Kohlmeier, L., Kent, K., Marcus, R.
(1997). Skeletal Effects of Cyclic Recombinant Human Growth Hormone and Salmon Calcitonin in Osteopenic Postmenopausal Women. J. Clin. Endocrinol. Metab.
82: 1111-1117
[Abstract][Full Text]
Adami, S, Fossaluzza, V, Gatti, D, Fracassi, E, Braga, V
(1997). Bisphosphonate therapy of reflex sympathetic dystrophy syndrome. Ann Rheum Dis
56: 201-204
[Abstract][Full Text]
Hodsman, A. B., Fraher, L. J., Watson, P. H., Ostbye, T., Stitt, L. W., Adachi, J. D., Taves, D. H., Drost, D.
(1997). A Randomized Controlled Trial to Compare the Efficacy of Cyclical Parathyroid Hormone Versus Cyclical Parathyroid Hormone and Sequential Calcitonin to Improve Bone Mass in Postmenopausal Women with Osteoporosis. J. Clin. Endocrinol. Metab.
82: 620-628
[Abstract][Full Text]
Bone, H. G., Downs, R. W. Jr., Tucci, J. R., Harris, S. T., Weinstein, R. S., Licata, A. A., McClung, M. R., Kimmel, D. B., Gertz, B. J., Hale, E., Polvino, W. J.
(1997). Dose-Response Relationships for Alendronate Treatment in Osteoporotic Elderly Women. J. Clin. Endocrinol. Metab.
82: 265-274
[Abstract][Full Text]
Delmas, P. D.
(1996). Bisphosphonates in the Treatment of Bone Diseases. NEJM
335: 1836-1837
[Full Text]
LANE, J. M., RILEY, E. H., WIRGANOWICZ, P. Z.
(1996). Instructional Course Lectures, The American Academy of Orthopaedic Surgeons - Osteoporosis: Diagnosis and Treatment*{{dagger}}. JBJS
78: 618-32
[Full Text]
Liberman, U. A., Weiss, S. R., Broll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J., Downs, R. W., Dequeker, J., Favus, M., Seeman, E., Recker, R. R., Capizzi, T., Santora, A. C., Lombardi, A., Shah, R. V., Hirsch, L. J., Karpf, D. B., The Alendronate Phase III Osteoporosis Treatment S,
(1995). Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis. NEJM
333: 1437-1444
[Abstract][Full Text]
Laitinen, K.
(1995). Use individual event rate adjustment for follow up time. BMJ
310: 1469b-1470
[Full Text]
Windeler, J., Lange, S.
(1995). Events per person year--a dubious concept. BMJ
310: 454-456
[Full Text]
Compston, J E
(1994). Fortnightly Review: The therapeutic use of bisphosphonates. BMJ
309: 711-715
[Full Text]
Sambrook, P., Birmingham, J., Kelly, P., Kempler, S., Nguyen, T., Pocock, N., Eisman, J.
(1993). Prevention of Corticosteroid Osteoporosis -- A Comparison of Calcium, Calcitriol, and Calcitonin. NEJM
328: 1747-1752
[Abstract][Full Text]
(1990). MORE EVIDENCE THAT ETIDRONATE IS EFFECTIVE IN OSTEOPOROSIS. JWatch General
1990: 3-3
[Full Text]
